

laboratory news

Sarah Lawton | +44 (0)1442 200654 sarah.lawton@synthesismedia.co.uk

Sales & Marketing

Andrew Long | +44 (0)1442 200659 andy.long@synthesismedia.co.uk

Account Manager

Lexi Taylor | +44 (0)1442 200655 lexi.taylor@synthesismedia.co.uk

Production / Design Steven Lillywhite CRE8 Design Studios Ltd steven.lillywhite@cre8designstudios.co.uk

Sean Marshall | +44 (0)1442 200651 sean.marshall@synthesismedia.co.uk

Circulation and subscriptions +44 (0)1442 200650 admin@synthesismedia.co.uk

Printing

Stephens & George Print Group



Castle House, 89 High Street, Berkhamsted, Hertfordshire, HP4 2DF www.labnews.co.uk



We publish 10 times per year and distribute to qualifying readers. The title is also available on subscription to other readers not qualifying for distribution at the following rates: UK £80.00

per annum; Europe £140.00 per annum; Rest of the world £160.00 per annum. Single copy: UK £6.00 Rest of the world £15.00. Charges for some of the colour pictures in this issue are being paid by the companies concerned. Laboratory News regrets it can not be held responsible for the safe return of documents or photographs, in any form, submitted for editorial consideration. Views expressed by contributors to this journal are not necessarily those of the publishers. While all reasonable care is taken when accepting advertisements, Synthesis Media accepts no responsibility for those appearing in Laboratory News.

© Copyright 2020 Synthesis Media ISSN 0266-7169

Terms and conditions for all competitions and giveaways can be found at www.labnews.co.uk



IN BRIEF

- 06 Focal Point Images of distinction
- **07** From the newsdesk Research, discovery, people and place
- Science Allsorts Round-up of the best things to read, watch and do

COMMENT / **INTERVIEW**

- **09** Quantum Survey Looking at the potential benefits of quantum computing technology in biopharma
- **10** Laboratology Dr Matthew Partridge offers advice on how to survive the middle of a research paper
- 11 Lab Babble Russ Swan takes a critical look at the UK vaccine effort and delivers a theory of his own
- 16 Guestbook Dermot Martin interviews 'The Vanadium Queen' for an update on VRFB development
- 18 The Big Ask The secrets behind the collaboration on the Integrated Genomics Toolkit (IGT)







IN DEPTH

- A luckier horseshoe
 An update on acceptance of
 Recombinant Factor C and
 horseshoe crab conservation
- 20 Process scale-up

 Managing thermal and pressure
 hazards at each stage of the
 production development
- 22 Feeding the world
 Investigating 75 emerging
 technologies to help feed the
 world sustainably
- 25 Technician commitment
 The Royal Society of Chemistry
 discusses why technicians need
 better support from the sector
- 26 Medical cannabis
 Why labs will need to become
 more adaptable to benefit from
 a growth market

THE KNOWLEDGE

- 32 Lab Management EU GMP Annex I for sterile product manufacturing contamination compliance
- 34 Think Tank
 Financial solutions to support
 cost-effective investments in
 new technologies
- The latest products to improve your results and help make your life in the lab a little easier



ON THE COVER

Lab Innovations 2020 investigates the use of legal cannabis-based products for medicinal use in humans (CBPMs)



AND FINALLY

- 50 Puzzles
- Our gaming experts take us through the world of scientific games and apps and ask... are they any good?

Are you developing IVDs or vaccines?

biopharma
group

Is time to market important?

Now's the time to talk to the experts in freeze drying production

Contact Biopharma Group Today: www.intelligentfreezedrying.com



Improving the luck of the horseshoe crab

Following some recent media controversy, Allen Burgenson, and Glenn Gauvry update our original July 2015 coverage and give us the real story behind the acceptance by the major *Pharmacopeia* of Recombinant Factor C for endotoxin testing and horseshoe crab conservation...


ndotoxin testing plays a critical role in safeguarding the world's injectable drug supply — ensuring vital medicines are free from potentially deadly bacterial endotoxins. The most widely used test for endotoxins, the Limulus Amebocyte Lysate (LAL) assay, uses the bright blue blood of the horseshoe crab as a key ingredient. Although the crabs are unharmed by the blood collection process and are returned alive to the sea afterwards, horseshoe crab populations in some parts of the world are in decline. With human health so dependent on these species for endotoxin testing, the biomedical industry is striving to ensure the sustainable future of these remarkable creatures.

Sustainable endotoxin testing

Alternative testing methods are considered key to reducing the biomedical industry's dependence on horseshoe crabs. One such method is the recombinant Factor C (rFC) assay, a sustainable test to detect bacterial endotoxins that does not rely on horseshoe crabs as the source material for the testing reagent. Lonza developed the first rFC assay based on technology discovered by biochemists Jeak L Ding and Bow Ho at the National University of Singapore¹ and introduced the PyroGene™ Assay to the market in 2003. The assay uses DNA from the horseshoe crab for expression in cell culture, meaning that no horseshoe crabs are involved in its production..

Validated in 2010, the rFC assay is only now being included in various global pharmacopeia — an important step in encouraging the pharma industry to adopt the recombinant test. In July this year, the European Pharmacopeia announced that a chapter describing the rFC assay will be effective as of 2021 as an alternative to LAL-based methods, while late last year the Japanese Pharmacopeia issued a draft chapter on alternative bacterial endotoxin tests (BET) using recombinant protein reagents. In January 2019, the rFC assay was also listed as a new compendial method for bacterial endotoxin testing in the Chinese Pharmacopeia.

The United States Pharmacopeia (USP) recently decided to forgo including the rFC assay in a unified chapter on BET. Instead, the USP will incorporate the rFC assay in a new chapter which, in line with other compendia, will describe the principles of assay validation and qualification of



alternative methods. While it is disappointing that the USP did not pursue the first unified bacterial endotoxin testing chapter that included rFC at this time, we look forward to the new chapter

and its eventual inclusion into the compendial bacterial endotoxin testing chapter. In the

> meantime, it's important to continue supporting the industry with both LAL and rFC testing options.

Horseshoe crab: A species under threat

Globally, Asian horseshoe crab numbers have been in decline for decades, with human behaviour threatening some species, particularly the crab *Thachypleus tridentatus*. In Asian

countries, these crabs are harvested for bait in conch and eel fishing, for Thachypleus Amoebocyte Lysate (TAL), traditional Chinese medicine, and for use as food, chitin and fertilizer. Additionally, their habitats are significantly impacted by coastal aquaculture, urban development and pollution.

Although the biomedical industry is still dependent on the collection of horseshoe crab blood for endotoxin testing, the sector has invested considerable effort into minimising its impact on crab populations. In 2011, the Atlantic States Marine Fisheries Commission (ASMFC), together with state representatives and LAL assay





1 JL Ding and B Ho. A new era in pyrogen testing. Trends in Biotechnology. 2001, 19 (8): 277-281. 2 Atlantic States Marine Fisheries Commission. 2019 Horseshoe Crab Benchmark Stock Assessment and Peer Review Report. 2019.

manufacturers, developed best practice guidance to reduce horseshoe crab mortality to levels as low as reasonably achievable. This includes guidance on night harvesting during the summer, as well as proper handling of the crabs during harvesting, transport, blood collection and return to the sea. Additionally, the guidance sets standards for the use of holding times of under 24 hours in clean, moist conditions, and recommends the collection of blood from individual crabs not more than once per year. These practices have been incorporated into LAL assay manufacturing procedures, and compliance is monitored by the Department of Natural Resources.

Findings from the ASMFC's 2019 Stock Assessment Report indicate that these efforts may be having a positive impact. While populations in the New York region are trending downwards, Southern, mid-Atlantic, and Northern populations in the United States are either stable or increasing.2

The biomedical industry continues to support horseshoe crab conservation efforts

The greatest threat to the world's four horseshoe crab species, as is the case with most threatened and endangered species, is ignorance and indifference. However, a significant factor contributing to horseshoe crab mortality is the species' annual intertidal spawning behaviour.

Every year, millions of adult crabs die through stranding upside-down on beaches following spawning activities.

Lonza participates in the "Just flip 'em!™" program, developed in 1998 by the Ecological Research and Development Group (ERDG), to rescue stranded crabs by flipping them over and returning them to the water. The "Just flip 'em!™" program brings attention to the large numbers of horseshoe crab deaths through stranding by encouraging individuals, through a simple act of compassion, to take the time to assist and appreciate these remarkable creatures.

Lonza's employees also have provided the funds to erect barrier fencing for an ERDG project on Pickering Beach, Delaware, preventing crabs from crossing over the beach into a lagoon where they would ultimately die. The barrier has prevented many thousands of crabs from perishing in this trap every year. By continuing our long involvement in horseshoe crab conservation efforts, and passionately pursuing the inclusion of rFC in a harmonised bacterial endotoxin testing chapter, the company seeks to protect the sustainable future of both endotoxin-safe medicines and horseshoe crab populations.





Allen Burgenson is Global Subject Matter Expert at Lonza Testing Solutions. Glenn Gauvry is **ERDG Founder** and Director at the Ecological Research & Development Group, a nonprofit wildlife conservation organisation.